Cases & Deals

  • Home
  • Practices
  • Isis expands patent portfolio related to bicyclic nucleic acids (BNAs) and antisense oligomers containing BNAs

Share

Isis expands patent portfolio related to bicyclic nucleic acids (BNAs) and antisense oligomers containing BNAs

January 2014

Client(s) Isis Pharmaceuticals, Inc.

Jones Day represented Isis Pharmaceuticals, Inc. (now Ionis Pharmaceuticals, Inc.) with the management and development of a patent portfolio related to bicyclic nucleic acids (BNAs) and antisense oligomers containing BNAs.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.